DEALS: Bausch & Lomb expands China operations


Bausch & Lomb expands China operations


DEALS

WHO

WITH

WHAT

SCOOP

Bausch & Lomb

Sino Biopharmaceutical

Buying 55% interest in Chinese ophthalmic unit

Bausch & Lomb expands its presence in the Chinese market.

Techne

Fortron Bio Science/BiosPacific

$20M buyout

Techne gains a developer and manufacturer of monoclonal and polyclonal antibodies, antigens and other biological reagents.

Qiagen

Nextal Biotechnology

$14.2M Buyout

Qiagen gains a provider of proprietary sample preparation tools which make protein crystallization more accessible.

Torrent Pharma

Pfizer

Generic division buyout

India's Torrent acquires Heumann Pharma Generics of Germany for an undisclosed amount.

Takara Bio

Becton, Dickinson and Company

Acquiring BD's Clontech division

Clontech develops, produces and markets biological products to the life science market.

Blairex Laboratories

Zila

Brand line sale, $10.3M

Blairex gains the Zilactin brand of OTC lip and oral care products.

Millipore

Microsafe

$9.3 million buyout

Millipore adds contract lab to its list of assets.

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.